BUZZ-Casi Pharmaceuticals falls after FDA puts experimental antibody drug on hold

** Casi Pharmaceuticals' CASI.O shares fall 14.89% to $2.40 premarket

** Co says its application to start trials for its experimental antibody in patients with a type of complication related to kidney transplants was placed on clinical hold

** The complication, known as Antibody Mediated Rejection, occurs after a transplant when the recipient's immune system produces antibodies that attack the transplanted organ

** Co's application supporting early-to-mid stage trial of the antibody in adults with chronic immune thrombocytopenia, a rare autoimmune blood disorder, remains open

** Up to last close, stock down ~60% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))